Investor Relations

Press Releases

Date Title and Summary View
Nov 01, 2018
Cash Expected to Enable Company to Fund Operations into Second Quarter 2019 PRINCETON, N.J. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three and nine months ended September 30, 2018 and provided
Oct 24, 2018
PRINCETON, N.J. , Oct. 24, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women’s healthcare company, today announced an oral presentation regarding predictors of pregnancy in the Phase 3 SECURE study of the investigational low-dose, once-weekly contraceptive patch, AG200-15
Oct 09, 2018
PRINCETON, N.J. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it has received a response from FDA’s Office of New Drugs (“OND”) concerning the Company’s formal dispute resolution request.  The Company had appealed the
Aug 03, 2018

Cash Expected to Enable Company to Fund Operations into Second Quarter 2019 PRINCETON, N.J. , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three and six months ended June 30, 2018 and provided a

Jul 24, 2018

Company Plans to Appeal to the FDA’s Office of New Drugs PRINCETON, N.J. , July 24, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq:AGRX) (the “Company”), a women’s healthcare company, today announced that the Office Director of the FDA’s Office of Drug Evaluation III (ODEIII) has

Jun 07, 2018

Cash Expected to Enable Company to Fund Operations into Second Quarter 2019 PRINCETON, N.J. , June 07, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq:AGRX), a women’s healthcare company, today announced several key corporate updates: Formal dispute resolution request has been submitted

May 18, 2018
PRINCETON, N.J., May 18, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX), a women's healthcare company, today announced the content of the official minutes from its Type A meeting with the U.S. Food and Drug Administration (FDA) held on April 16, 2018 to discuss the complete
May 07, 2018
Current Business Plan Expected to Enable Cash to Fund Operations through the end of 2018
Mar 14, 2018
PRINCETON, N.J., March 14, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX), a women's healthcare company today announced that an abstract related to the Phase 3 SECURE study for AG200-15 (Twirla ® ), an investigational, once-weekly, low-dose hormonal contraceptive patch, has been
Mar 12, 2018
Current Business Plan Expected to Enable Cash to Fund Operations through the end of 2018